Ophthalmic biosimilars: Lessons from India.
作者信息
Sharma Ashish, Kumar Nilesh, Kuppermann Baruch D, Francesco Bandello, Lowenstein Anat
机构信息
Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India.
Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
出版信息
Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19.
Abstract
摘要
相似文献
1
Ophthalmic biosimilars: Lessons from India.
Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19.
2
Biosimilars for Retinal Diseases: An Update.
Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9.
3
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
4
Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity.
Indian J Ophthalmol. 2019 Jun;67(6):967-969. doi: 10.4103/ijo.IJO_884_17.
5
The brave new world of biosimilars ('similar biologics') in India.
Postgrad Med J. 2017 Oct;93(1104):577-579. doi: 10.1136/postgradmedj-2017-134806. Epub 2017 May 25.
6
Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.
JAMA Ophthalmol. 2018 Dec 1;136(12):1352-1358. doi: 10.1001/jamaophthalmol.2018.3939.
7
Razumab -- the role of biosimilars for the treatment of retinal diseases.
Drugs Today (Barc). 2021 Aug;57(8):499-505. doi: 10.1358/dot.2021.57.8.3284618.
8
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs.
Eye (Lond). 2024 Jul;38(10):1796-1798. doi: 10.1038/s41433-024-03001-8. Epub 2024 Mar 4.
9
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
10
Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.
J Med Assoc Thai. 2015 May;98(5):489-94.
引用本文的文献
1
Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.
Eye (Lond). 2025 Apr;39(6):1026-1027. doi: 10.1038/s41433-025-03732-2. Epub 2025 Feb 19.
2
Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study.
Clin Ophthalmol. 2024 Nov 25;18:3449-3456. doi: 10.2147/OPTH.S500912. eCollection 2024.
3
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI).
Eye (Lond). 2024 Dec;38(17):3392-3395. doi: 10.1038/s41433-024-03284-x. Epub 2024 Aug 26.
4
Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study.
Clin Ophthalmol. 2024 Jun 24;18:1819-1828. doi: 10.2147/OPTH.S459085. eCollection 2024.
5
Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders.
Pharmaceuticals (Basel). 2023 Aug 11;16(8):1140. doi: 10.3390/ph16081140.
6
Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection.
J Vitreoretin Dis. 2022 Sep 8;6(6):443-451. doi: 10.1177/24741264221116487. eCollection 2022 Nov-Dec.
7
Commentary: Biosimilars in the treatment of retinopathy of prematurity.
Indian J Ophthalmol. 2023 Feb;71(2):416-417. doi: 10.4103/ijo.IJO_2254_22.
8
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications.
Cells. 2022 Oct 25;11(21):3362. doi: 10.3390/cells11213362.
9
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis in patients with neovascular age-related macular degeneration.
Indian J Ophthalmol. 2022 Aug;70(8):3008-3014. doi: 10.4103/ijo.IJO_2118_21.
10
Retina: a unique subspecialty in the biosimilar landscape.
Eye (Lond). 2022 Jun;36(6):1145-1146. doi: 10.1038/s41433-022-01984-w. Epub 2022 Feb 21.
本文引用的文献
1
Biotherapeutics and immunogenicity: ophthalmic perspective.
Eye (Lond). 2019 Sep;33(9):1359-1361. doi: 10.1038/s41433-019-0434-y. Epub 2019 Apr 9.
2
Biosimilars in ophthalmology: "Is there a big change on the horizon?".
Clin Ophthalmol. 2018 Oct 24;12:2137-2143. doi: 10.2147/OPTH.S180393. eCollection 2018.
3
Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Ophthalmic Epidemiol. 2016;23(2):71-9. doi: 10.3109/09286586.2015.1090004. Epub 2016 Feb 8.
Zotero 插件